The Current Ratio as of August 2024 (TTM) for Cerevel Therapeutics Holdings, Inc. (CERE) is 10.22

According to Cerevel Therapeutics Holdings, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 10.22. This represents a change of -1.09% compared to the average of 10.33 of the last 4 quarters.

Cerevel Therapeutics Holdings, Inc. (CERE) Historical Current Ratio (quarterly & annually)

How has CERE Current Ratio performed in the past?

The mean historical Current Ratio of Cerevel Therapeutics Holdings, Inc. over the last ten years is 8.13. The current 10.22 Current Ratio has changed 12.47% with respect to the historical average. Over the past ten years (40 quarters), CERE's Current Ratio was at its highest in in the September 2021 quarter at 21.92. The Current Ratio was at its lowest in in the March 2019 quarter at 0.

Cerevel Therapeutics Holdings, Inc. (CERE) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Cerevel Therapeutics Holdings, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Cerevel Therapeutics Holdings, Inc. (CERE) Average Current Ratio

How has CERE Current Ratio performed in the past?

The current Current Ratio of Cerevel Therapeutics Holdings, Inc. (CERE) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Cerevel Therapeutics Holdings, Inc. (CERE) Current Ratio vs. Peers

How is CERE’s Current Ratio compared to its peers?

Cerevel Therapeutics Holdings, Inc.’s Current Ratio is less than Avidity Biosciences, Inc. (15.78), less than Revolution Medicines, Inc. (15.42), greater than Day One Biopharmaceuticals, Inc. (4.09), greater than SpringWorks Therapeutics, Inc. (7.91), less than Ventyx Biosciences, Inc. (14.19), less than Nuvalent, Inc. (17.44), greater than Travere Therapeutics, Inc. (3.04), less than Structure Therapeutics Inc. (41.38), greater than Monte Rosa Therapeutics, Inc. (6.56), less than Design Therapeutics, Inc. (41.42), less than Werewolf Therapeutics, Inc. (12.13), less than Ikena Oncology, Inc. (18.22), greater than Stoke Therapeutics, Inc. (6.67), greater than Apellis Pharmaceuticals, Inc. (5.08), less than Terns Pharmaceuticals, Inc. (21.02), greater than Blueprint Medicines Corporation (3.71), greater than IGM Biosciences, Inc. (7.06), less than Cullinan Oncology, Inc. (28.87), less than Mineralys Therapeutics, Inc. (11.20),

Build a custom stock screener for Cerevel Therapeutics Holdings, Inc. (CERE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cerevel Therapeutics Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cerevel Therapeutics Holdings, Inc. (CERE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cerevel Therapeutics Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.